Rotate to portrait

Vizual Stocks works best vertically on mobile.

VizualStocks API
PUBLIC DATA DEFINITIONS

VistaGen Therapeutics KPI & segment coverage

Operating KPI and segment definitions available for VistaGen Therapeutics (VTGN) through the VizualStocks API.

VTGN3 metric seriesCatalog checked 2026-10-28
Metric catalog API reference Open in the interactive demo

Active metrics 3

SEGMENT

Affamed Collaboration Revenue

Revenue recognized during the period under Vistagen's AffaMed agreement for fasedienol licensing and related development and regulatory services in Greater China, South Korea and specified Southeast Asian markets. It excludes Fuji Pharma negotiation-agreement revenue and represents accounting revenue rather than cash receipts or potential milestone payments.

affamedCollaborationRevenue
Frequency
quarterly / annual
Reported history
Q2'21 — Q2'26
History endpoint
COMPANY KPI

Fasedienol Development Expense

Clinical and nonclinical study and development expenses assigned to Vistagen's fasedienol (formerly PH94B) program during the period. The measure excludes separately reported shared R&D personnel, stock compensation, consulting and occupancy costs and is not total R&D or cash paid.

fasedienolDevelopmentExpense
Frequency
quarterly / annual
Reported history
Q2'23 — Q2'26
History endpoint
COMPANY KPI

Other Clinical Development Expense

Clinical and nonclinical study and development expenses assigned to Vistagen's programs other than fasedienol during the period, using the issuer's reported program grouping. It excludes fasedienol and separately reported shared R&D cost categories; the underlying candidate mix can change over time.

otherClinicalDevelopmentExpense
Frequency
quarterly / annual
Reported history
Q2'23 — Q2'26
History endpoint